One-Liner
A patient navigation tool for Brazilian and Indonesian middle-class diabetics to find locally licensed GLP-1 variants as cross-border pharmaceutical IP flow accelerates.
AI Thinking Process
BioPharma signal: Madrigal bought GLP-1 IP from China's CSPC; cross-border GLP-1 IP flow accelerating
G167: ClinicalTrials.gov / Antidote / TrialJectory don't focus on cross-border IP flow. ANVISA/BPOM publish licensing decisions but not patient-friendly. Artifact is unowned.
WHO: Middle-class Brazilian/Indonesian T2 diabetic age 40-65, willing to pay out-of-pocket; CURRENT: WhatsApp groups, Instagram influencers, opportunistic gray market
G166 check: emerging-market patient artifact ownership — passes redirect rule (not Western consumer clinical-interpretation)
Trust/safety worry: gray market GLP-1 is real harm vector; must aggressively filter unlicensed sources
Pass 1 survived at 35% (bumped from 32% to be at flavor floor). Pass 2 must test moat vs window and verify Indonesia data.
Brazil semaglutide patent expired March 20, 2026 (same day as India). Biocon-Biomm deal confirmed cross-border IP flow. ANVISA has 17 semaglutide products under review.
Indonesia BPOM cross-border GLP-1 data not verified — web search returned no meaningful Indonesia BPOM patient-facing resources on GLP-1
TEMPLATE gate: overlaps with Oral GLP-1 India (same template, two geographies). India is the stronger sibling — single-country focus, validated regulatory date, concrete channels, no missing-data leg. Brazil+Indonesia product is also structurally incoherent (Brazil=drug lookup, Indonesia=telehealth referral). Conviction dropped to 24%.
Kill Reason
Template gate failure: overlaps structurally with Oral GLP-1 India (same emerging-market GLP-1 consumer app template in same patent-expiry window). The India version has stronger validation, cleaner single-country focus, and no missing-data leg. Brazil + Indonesia product also has structural split: Brazil = drug lookup, Indonesia = telehealth referral — two half-products, not one.
Risk Analysis
Risk analysis available for latest engine ideas.
Loading...
Related ideas you can explore free:
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.
killed: Template epidemic (G003) + industry-pain-form death pattern (G005) fire simultaneously. 13+ existing compliance tools. A prompt could do 80% of this.